Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
CONCLUSION: The present results suggest that TOF is more effective with regard to remission at week 52 based on treatment responses in SE-negative RA patients.PMID:36407801 | PMC:PMC9667967 | DOI:10.1093/rap/rkac090 (Source: Herpes)
Source: Herpes - November 21, 2022 Category: Infectious Diseases Authors: Wataru Hirose Masayoshi Harigai Koichi Amano Toshihiko Hidaka Kenji Itoh Kazutoshi Aoki Masahiro Nakashima Hayato Nagasawa Yukiko Komano Toshihiro Nanki Source Type: research
Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
CONCLUSION: The present results suggest that TOF is more effective with regard to remission at week 52 based on treatment responses in SE-negative RA patients.PMID:36407801 | PMC:PMC9667967 | DOI:10.1093/rap/rkac090 (Source: Herpes)
Source: Herpes - November 21, 2022 Category: Infectious Diseases Authors: Wataru Hirose Masayoshi Harigai Koichi Amano Toshihiko Hidaka Kenji Itoh Kazutoshi Aoki Masahiro Nakashima Hayato Nagasawa Yukiko Komano Toshihiro Nanki Source Type: research
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase ®)
ConclusionWe identified possible associations with some adverse fetal and neonatal outcomes, suggesting that vigilance is required when prescribing certain biologics during pregnancy. (Source: BioDrugs)
Source: BioDrugs - November 19, 2022 Category: Drugs & Pharmacology Source Type: research
Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data
by Eiichi Tanaka, Eisuke Inoue, Ayako Shoji, Jonas Nilsson, Christos Papagiannopoulos, Devender Dhanda, Yuri Yoshizawa, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka, Masayoshi Harigai
ObjectivesTo investigate the cost-effectiveness of abatacept (ABA) as first-line (1L) therapy in Japanese rheumatoid arthritis (RA) patients using data from the Institute of Rheumatology, Rheumatoid Arthritis database. MethodsA decision-analytic model was used to estimate the cost per American College of Rheumatology response of at least 50% improvement (ACR50) responder an...
Source: PLoS One - November 16, 2022 Category: Biomedical Science Authors: Eiichi Tanaka Source Type: research
Human immunomodulatory ligand B7-1 mediates synaptic remodeling via the p75 neurotrophin receptor
Cell surface receptors, ligands, and adhesion molecules underlie development, circuit formation, and synaptic function of the central nervous system and represent important therapeutic targets for many neuropathologies. The functional contributions of interactions between cell surface proteins of neurons and nonneuronal cells have not been fully addressed. Using an unbiased protein-protein interaction screen, we showed that the human immunomodulatory ligand B7-1 (hB7-1) interacts with the p75 neurotrophin receptor (p75NTR) and that the B7-1:p75NTR interaction is a recent evolutionary adaptation present in humans and other ...
Source: Journal of Clinical Investigation - November 15, 2022 Category: Biomedical Science Authors: Nicholas C. Morano, Roshelle S. Smith, Victor Danelon, Ryan Schreiner, Uttsav Patel, Natalia G. Herrera, Carla Smith, Steven M. Olson, Michelle K. Laerke, Alev Celikgil, Scott J. Garforth, Sarah C. Garrett-Thomson, Francis S. Lee, Barbara L. Hempstead, St Source Type: research
The Combination of Dupilumab with Other Monoclonal Antibodies
ConclusionsBecause the evidence is modest, the question remains open as to whether dupilumab can be safely combined with other monoclonal antibodies. Dupilumab does not exert immunosuppressive effects and does not impair the activity of cytochrome P450 isozymes. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - November 10, 2022 Category: Dermatology Source Type: research
Uncover diagnostic immunity/hypoxia/ferroptosis/epithelial mesenchymal transformation-related CCR5, CD86, CD8A, ITGAM, and PTPRC in kidney transplantation patients with allograft rejection
In conclusion, the study could be useful in understanding changes in the microenvironment within transplantation, which may promote or sustain the development of allograft rejection after kidney transplantation.PMID:36330810 | DOI:10.1080/0886022X.2022.2141648 (Source: Renal Failure)
Source: Renal Failure - November 4, 2022 Category: Urology & Nephrology Authors: Long He Boqian Wang Xueyi Wang Yuewen Liu Xing Song Yijian Zhang Xin Li Hongwei Yang Source Type: research
Comparative Efficacy and Safety of Biological Agents in the Treatment of Lupus Nephritis: A Network Meta-Analysis
Conclusions: Low-dose IL-2 was the most effective induction treatment for patients with lupus nephritis and had the lowest potential for SAE. Higher complete remission rates and a more favorable safety profile suggest that low-dose IL-2, obinutuzumab, rituximab, and belimumab may be superior to the current control as treatments for lupus nephritis.Pharmacology (Source: Pharmacology)
Source: Pharmacology - November 3, 2022 Category: Drugs & Pharmacology Source Type: research
Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
(Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - November 3, 2022 Category: Rheumatology Authors: Martin Bergman, Namita Tundia, Naomi Martin, Jessica L. Suboticki, Jayeshkumar Patel, Debbie Goldschmidt, Yan Song and Grace C. Wright Tags: Correction Source Type: research
Treatment of severe COVID-19: an evolving paradigm
Expert Opin Pharmacother. 2022 Oct 21. doi: 10.1080/14656566.2022.2140041. Online ahead of print.ABSTRACTINTRODUCTION: The pathogenesis of severe COVID-19 is due, in part, to dysregulation of the human immune system in response to SARS-CoV-2 infection. Immune cells infected with SARS-CoV-2 can trigger a hyperinflammatory response of both the adaptive and innate immune system that has been associated with severe disease, hospitalization, and death, and better treatment options are urgently needed.AREAS COVERED: A mainstay of therapy for COVID-19 involves an antiviral agent, remdesivir, in combination with a systemic cortico...
Source: Expert Opinion on Pharmacotherapy - October 22, 2022 Category: Drugs & Pharmacology Authors: Matthew W McCarthy Source Type: research
